Daiichi Sankyo Company, Limited — Ethics Grade C-

Daiichi Sankyo Company, Limited receives an overall ethics grade of C- (48/100) on CancelCo's corporate accountability database. Sector: Healthcare. Market cap: Large Cap.

Category scores

• labor: 70
• privacy: 80
• consumer: 30
• environment: 65
• humanRights: 60

Documented incidents (3)

• Generic Drug Safety Fraud (high, 2013) — Subsidiary Ranbaxy pleaded guilty to felony charges relating to the manufacture and distribution of adulterated drugs. The company paid $500 million to settle allegations of falsifying data and poor quality control.
• Misleading Benicar Claims (medium, 2015) — The company agreed to pay $39 million to settle claims that it made false and misleading statements about the blood pressure drug Benicar. Allegations included claims that it was superior to other drugs without clinical evidence.
• Illegal Physician Kickbacks (high, 2015) — Daiichi Sankyo paid $39 million to resolve False Claims Act allegations that it paid kickbacks to physicians to induce them to prescribe its drugs. The payments were disguised as speaker fees and lavish meals.

Documented good deeds

• Access to Medicine Expansion — The company expanded its mobile clinic program in rural Asia and Africa, providing basic healthcare and medicine to underserved populations.

Ethical alternatives

• Novo Nordisk — Stronger ethical oversight and transparency in drug pricing.